Dr Dunn leads a discussion outlining frontline therapies for the treatment of vitiligo. Jeffrey D. Dunn, PharmD, MBA: What therapies are being used? Are they generally covered by different books of ...
David Epstein, MD, MBA, an independent consultant, gives an overview of payer considerations surrounding vitiligo. Jeffrey D. Dunn, PharmD, MBA: Let me go down that path a little further and bring Dr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results